Satellos Bioscience (MSCL) Q4 2025 earnings summary

Executive summary

• Completed $57.2 million equity financing and began trading on Nasdaq under ticker "MSLE" in February 2026.

• Initiated two Phase 2 clinical trials (BASECAMP and TRAILHEAD) for SAT-3247 in Duchenne muscular dystrophy (DMD).

• Presented positive interim clinical and preclinical data at the 2026 MDA Conference, including sustained grip strength improvements and biomarker validation.

• Cash runway projected to extend through 2027.

Financial highlights

• Cash and equivalents were $27.7 million as of Dec. 31, 2025, down from $48.5 million a year earlier, mainly due to increased clinical trial spending.

• Net loss for 2025 was $24.9 million ($1.70 per share), compared to $20.6 million ($2.16 per share) in 2024, reflecting higher R&D and G&A expenses.

• R&D expenses rose to $18.4 million from $14.4 million year-over-year, driven by Phase 2 trial initiation.

• G&A expenses increased to $8.0 million from $6.0 million, due to higher headcount and public company costs.

• Subsequent to year-end, raised $57.2 million in gross proceeds from a public offering.

Outlook and guidance

• BASECAMP trial enrollment expected to complete in Q3 2026, with top-line data in Q4 2026.

• Plans to expand TRAILHEAD enrollment in Australia and the U.S., targeting up to 30 adult DMD participants.

• Anticipates meaningful clinical progress and updates in 2026 for SAT-3247 as a potential disease-modifying therapy.